Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 14, 2026, 8:34 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 169–192 of 302 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Cerebellar Disorders Clear all

Conditions: Leukodystrophy, White Matter Disease, Leukoencephalopathies, 4H Syndrome, Adrenoleukodystrophy, AMN, ALD, ALD Gene Mutation, ALD (Adrenoleukodystrophy), X-linked Adrenoleukodystrophy, X-ALD, Adrenomyeloneuropathy, Aicardi Goutieres Syndrome, AGS, Alexander Disease, Alexanders Leukodystrophy, AxD, ADLD, Canavan Disease, CTX, Cerebrotendinous Xanthomatoses, Krabbe Disease, GALC Deficiency, Globoid Leukodystrophy, TUBB4A-Related Leukodystrophy, H-ABC - Hypomyelination, Atrophy of Basal Ganglia and Cerebellum, HBSL, HBSL - Hypomyelination, Brain Stem, Spinal Cord, Leg Spasticity, LBSL, Leukoencephalopathy With Brain Stem and Spinal Cord Involvement and High Lactate Syndrome (Disorder), Leukoencephalopathy With Brainstem and Spinal Cord Involvement and Lactate Elevation, ALSP, CSF1R Gene Mutation, HCC - Hypomyelination and Congenital Cataract, MLC1, Megalencephalic Leukoencephalopathy With Subcortical Cysts, MLD, Metachromatic Leukodystrophy, PMD, Pelizaeus-Merzbacher Disease, PLP1 Null Syndrome, PLP1 Gene Duplication &#X7C; Blood or Tissue &#X7C; Mutations, Pelizaeus Merzbacher Like Disease, Peroxisomal Biogenesis Disorder, Zellweger Syndrome, Refsum Disease, Salla Disease, Sialic Storage Disease, Sjögren, Sjogren-Larsson Syndrome, Van Der Knapp Disease, Vanishing White Matter Disease, Charcot-Marie-Tooth, CMT, Mct8 (Slc16A2)-Specific Thyroid Hormone Cell Transporter Deficiency, Allan-Herndon-Dudley Syndrome, Cadasil, Cockayne Syndrome, Multiple Sulfatase Deficiency, Gangliosidoses, GM2 Gangliosidosis, BPAN, Labrune Syndrome, LCC, Mucopolysaccharidoses, TBCK-Related Intellectual Disability Syndrome
Interventions: Not listed
Lead sponsor: Children's Hospital of Philadelphia; Other
Eligibility: Not listed
Enrollment: 12,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2030
U.S. locations: 24
States / cities: Los Angeles, California • Orange, California • Palo Alto, California + 19 more

Conditions: Friedreich's Ataxia
Interventions: Placebo, EPI-743 400 mg, EPI-743 200 mg; Drug
Lead sponsor: PTC Therapeutics; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 3
States / cities: Los Angeles, California • Tampa, Florida • Philadelphia, Pennsylvania

Conditions: Chemically-Induced Disorders, Substance-Related Disorders, Mental Disorders, Alcohol Dependence, Alcohol-Related Disorders
Interventions: Not listed
Lead sponsor: National Institute on Alcohol Abuse and Alcoholism (NIAAA); NIH
Eligibility: 30 Years to 60 Years
Enrollment: 98 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Spinocerebellar Ataxia Type 3
Interventions: BIIB132, BIIB132-Matching Placebo; Drug
Lead sponsor: Biogen; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 10
States / cities: Los Angeles, California • San Francisco, California • Gainesville, Florida + 7 more

Conditions: Friedreich Ataxia, Friedreich's Ataxia
Interventions: Nomlabofusp, Placebo; Drug
Lead sponsor: Larimar Therapeutics, Inc.; Industry
Eligibility: 12 Years to 40 Years
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 4
States / cities: Tampa, Florida • Chicago, Illinois • Eatontown, New Jersey + 1 more

Conditions: Vestibular Disorder, Fall, Coordination and Balance Disturbances
Interventions: Vestibular Rehabilitation; Other
Lead sponsor: Methodist University, North Carolina; Other
Eligibility: Female only
Enrollment: 1 participant
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Fayetteville, North Carolina

Conditions: Colorectal Neoplasms
Interventions: Vicriviroc, Pembrolizumab; Drug · Biological
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 41 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 6
States / cities: Scottsdale, Arizona • Encinitas, California • Fresno, California + 3 more

Conditions: Friedreich's Ataxia
Interventions: Not listed
Lead sponsor: University of Florida; Other
Eligibility: 6 Years to 70 Years
Enrollment: 203 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2030
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: Spinocerebellar Ataxia Type 6
Interventions: Not listed
Lead sponsor: University of Chicago; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Multiple Sclerosis, Optic Neuritis, Transverse Myelitis, Acute Brainstem/Cerebellar Syndrome
Interventions: interferon beta 1a 30 ug IM once weekly; Drug
Lead sponsor: Beth Israel Deaconess Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 155 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2009
U.S. locations: 20
States / cities: Derby, Connecticut • Tampa, Florida • Atlanta, Georgia + 16 more

Conditions: Spinocerebellar Ataxia Type 1, Spinocerebellar Ataxia Type 2, Spinocerebellar Ataxia Type 3, Spinocerebellar Ataxia Type 6, Spinocerebellar Ataxia Type 7
Interventions: High-Intensity Aerobic Exercise Prior to Balance Training, Low-Intensity Exercise Prior to Balance Training; Behavioral
Lead sponsor: Teachers College, Columbia University; Other
Eligibility: 18 Years to 85 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: New York, New York

Conditions: Brain and Central Nervous System Tumors, Kidney Cancer, Liver Cancer, Retinoblastoma, Sarcoma
Interventions: filgrastim, busulfan, etoposide, ifosfamide, melphalan, thiotepa, stem cell transplantation, tomotherapy, total marrow irradiation, Mesna, Whole lung radiation; Biological · Drug · Procedure + 1 more
Lead sponsor: Masonic Cancer Center, University of Minnesota; Other
Eligibility: Up to 70 Years
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2016
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Cerebrovascular Stroke
Interventions: Fast intervention, Active Monitoring; Behavioral
Lead sponsor: University of Southern California; Other
Eligibility: 21 Years and older
Enrollment: 44 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Pomona, California

Conditions: Autism Spectrum Disorder
Interventions: tDCS; Device
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 4 Years to 17 Years
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2027
U.S. locations: 2
States / cities: Dallas, Texas

Conditions: Autism Spectrum Disorder
Interventions: trans cranial direct current stimulation (tDCS), Sham; Device
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 5 Years to 21 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: Dalls, Texas

Conditions: Brain and Central Nervous System Tumors, Carcinoma of Unknown Primary, Leukemia, Lymphoma, Unspecified Childhood Solid Tumor, Protocol Specific
Interventions: topotecan hydrochloride; Drug
Lead sponsor: Pediatric Brain Tumor Consortium; Network
Eligibility: 3 Years to 21 Years
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2005
U.S. locations: 11
States / cities: San Francisco, California • Washington D.C., District of Columbia • Chicago, Illinois + 8 more

Conditions: Huntington's Disease
Interventions: Not listed
Lead sponsor: Peggy C Nopoulos; Other
Eligibility: 6 Years to 30 Years
Enrollment: 488 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2026
U.S. locations: 6
States / cities: Sacramento, California • Iowa City, Iowa • New York, New York + 3 more

Conditions: Friedreich Ataxia, Neuro-Degenerative Disease
Interventions: Not listed
Lead sponsor: Friedreich's Ataxia Research Alliance; Other
Eligibility: 4 Years to 80 Years
Enrollment: 2,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2001 – 2030
U.S. locations: 9
States / cities: Los Angeles, California • Denver, Colorado • Gainesville, Florida + 6 more

Conditions: Friedreich's Ataxia
Interventions: Interferon γ-1b; Drug
Lead sponsor: Amgen; Industry
Eligibility: 10 Years to 26 Years
Enrollment: 86 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 4
States / cities: Los Angeles, California • Gainesville, Florida • Iowa City, Iowa + 1 more

Conditions: Brain and Central Nervous System Tumors, Neuroblastoma
Interventions: enzastaurin hydrochloride; Drug
Lead sponsor: Pediatric Brain Tumor Consortium; Network
Eligibility: Up to 21 Years
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 8
States / cities: San Francisco, California • Washington D.C., District of Columbia • Chicago, Illinois + 5 more

Conditions: Multiple Sclerosis
Interventions: Sham Transcranial Direct Current Stimulation (tDCS), Balance Training, 2 mA Transcranial Direct Current Stimulation, 4 mA Transcranial Direct Current Stimulation; Device · Behavioral
Lead sponsor: University of Iowa; Other
Eligibility: 18 Years to 70 Years
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Iowa City, Iowa

Conditions: Stiff-Person Syndrome
Interventions: Autologous Hematopoietic Stem Cells, Cyclophosphamide, Mesna, rATG, Methylprednisolone, G-CSF, Rituxan; Biological · Drug
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years to 60 Years
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2019
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Spinocerebellar Ataxias, Spinocerebellar Ataxia Genotype Type 1, Spinocerebellar Ataxia Genotype Type 2, Spinocerebellar Ataxia Genotype Type 3, Spinocerebellar Ataxia Genotype Type 6, Spinocerebellar Ataxia Genotype Type 7, Spinocerebellar Ataxia Genotype Type 8, Spinocerebellar Ataxia Genotype Type 10
Interventions: Troriluzole, Placebo; Drug
Lead sponsor: Biohaven Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 141 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2024
U.S. locations: 18
States / cities: Phoenix, Arizona • Long Beach, California • Los Angeles, California + 13 more

Conditions: Essential Tremor, Parkinson Disease, Huntington Disease, Dystonia, Primary, Spinocerebellar Ataxias, Movement Disorders
Interventions: Not listed
Lead sponsor: Rutgers, The State University of New Jersey; Other
Eligibility: 18 Years to 80 Years
Enrollment: 210 participants
Timeline: 2019 – 2022
U.S. locations: 1
States / cities: Newark, New Jersey

Search by objective public record fields.

The Myelin Disorders Biorepository Project

Safety and Efficacy of EPI-743 in Patients With Friedreich's Ataxia

Study of Structural Imaging

A Pharmacokinetics and Safety Study of BIIB132 in Adults With Spinocerebellar Ataxia 3

A Study to Evaluate the Efficacy and Safety of Subcutaneous Nomlabofusp in Subjects With Friedreich's Ataxia

Vestibular Rehabilitation for Chronic Central Vestibular Deficits: A Case Study

Safety and Efficacy of Vicriviroc (MK-7690) in Combination With Pembrolizumab (MK-3475) in Participants With Advanced/Metastatic Microsatellite Stable (MSS) Colorectal Cancer (CRC) (MK-7690-046)

Biomarkers in Friedreich's Ataxia

Parkinsonism in Spinocerebellar Ataxia Type 6

Long Term Study of Avonex Therapy Following a First Attack of Multiple Sclerosis

Priming Motor Learning Through Exercise in People With Spinocerebellar Ataxia

MT2004-30: Tomotherapy for Solid Tumors

Fast Arm Motor Skill Training in Chronic Stroke Survivors

Cerebellar tDCS in Children With Autism Spectrum Disorder

Cerebellar Transcranial Direct Current Stimulation (tDCS) in Children With Autism Spectrum Disorder: Raynor Cerebellum Project

Topotecan in Treating Young Patients With Neoplastic Meningitis Due to Leukemia, Lymphoma, or Solid Tumors

Child to Adult Neurodevelopment in Gene Expanded Huntington's Disease

FA Clinical Outcome Measures

Safety, Tolerability and Efficacy of ACTIMMUNE® Dose Escalation in Friedreich's Ataxia Study

Enzastaurin in Treating Young Patients With Refractory Primary CNS Tumors

Cerebellar tDCS and Balance Training in PwMS

Stem Cell Transplantation for Stiff Person Syndrome (SPS)

Trial in Adult Participants With Spinocerebellar Ataxia (SCA)

Using Wearable and Mobile Data to Diagnose and Monitor Movement Disorders